Company Overview and News

3
Share Buyback Programme: Transactions in Week Ten

2018-10-15 globenewswire
Guernsey, 15 October 2018 – Eurocastle Investment Limited (“Eurocastle” or the “Company”) today announces that between 8 October 2018 and 12 October 2018, as part of the previously announced buyback programme entered into with Liberum Capital Limited (acting as the Company's broker), it bought back 17,703 of its ordinary shares at an average price of €6.58 per ordinary share. These purchases were made pursuant to the authority granted at its Annual General Meeting on 20 June 2018.
FIG

3
Fortress Transportation and Infrastructure Investors LLC Announces Timing of Third Quarter 2018 Earnings and Conference Call

2018-10-08 globenewswire
NEW YORK, Oct. 08, 2018 (GLOBE NEWSWIRE) -- Fortress Transportation and Infrastructure Investors LLC (NYSE:FTAI; the "Company") plans to announce its financial results for the third quarter 2018 after the closing of the New York Stock Exchange on Thursday, November 1, 2018. A copy of the press release and an earnings supplement will be posted to the Investor Relations section of the Company's website, www.
FIG FTAI DTK

3
Eurocastle Investment Limited: Share Buyback Programme: Transactions in Week Nine

2018-10-08 globenewswire
Guernsey, 8 October 2018 – Eurocastle Investment Limited (“Eurocastle” or the “Company”) today announces that between 1 October 2018 and 5 October 2018, as part of the previously announced buyback programme entered into with Liberum Capital Limited (acting as the Company's broker), it bought back 11,438 of its ordinary shares at an average price of €6.66 per ordinary share. These purchases were made pursuant to the authority granted at its Annual General Meeting on 20 June 2018.
FIG

3
CryptoWatch: Bitcoin prices may not have hit rock bottom yet, says Cboe options expert

2018-09-24 marketwatch
Coming off the best week for digital currencies since late July, bitcoin, the world’s No. 1 digital currency, was trading marginally lower on Monday.
FIG 7018 CME

3
Eurocastle Investment Limited: Share Buyback Programme: Transactions in Week Seven

2018-09-24 globenewswire
Guernsey, 24 September 2018 – Eurocastle Investment Limited (“Eurocastle” or the “Company”) today announces that between 17 September 2018 and 21 September 2018, as part of the previously announced buyback programme entered into with Liberum Capital Limited (acting as the Company's broker), it bought back 11,974 of its ordinary shares at an average price of €6.75 per ordinary share. These purchases were made pursuant to the authority granted at its Annual General Meeting on 20 June 2018.
FIG

8
Cryptocurrency has hit bottom, bitcoin due for renaissance: Novogratz

2018-09-20 channelnewsasia
Michael Novogratz, former macro hedge fund manager and founder of cryptocurrency asset management firm Galaxy Digital Capital Management, on Thursday said that the bottom in cryptocurrency prices has been reached and bitcoin is due to bounce back.
JBK GSC TFG GSJ TLRY FIG GS GLSSP GJS

8
UPDATE 2-Cryptocurrency has hit bottom, bitcoin due for renaissance -Novogratz

2018-09-20 reuters
NEW YORK (Reuters) - Michael Novogratz, former macro hedge fund manager and founder of cryptocurrency asset management firm Galaxy Digital Capital Management, on Thursday said that the bottom in cryptocurrency prices has been reached and bitcoin is due to bounce back.
JBK GSC TFG GSJ TLRY FIG GS GLSSP GJS

8
Novogratz says crypto hit bottom, bitcoin due for renaissance -Yahoo summit

2018-09-20 reuters
NEW YORK, Sept 20 (Reuters) - Michael Novogratz, former macro hedge fund manager and founder of cryptocurrency asset management firm Galaxy Digital Capital Management, on Thursday said that the bottom in cryptocurrency prices has been reached and bitcoin is due for a renaissance.
JBK GSC TFG GSJ FIG GS GLSSP GJS

3
Eurocastle Investment Limited: Share Buyback Programme: Transactions in Week Six

2018-09-17 globenewswire
Guernsey, 17 September 2018 – Eurocastle Investment Limited (“Eurocastle” or the “Company”) today announces that between 10 September 2018 and 14 September 2018, as part of the previously announced buyback programme entered into with Liberum Capital Limited (acting as the Company's broker), it bought back 16,611 of its ordinary shares at an average price of €6.79 per ordinary share. These purchases were made pursuant to the authority granted at its Annual General Meeting on 20 June 2018.
FIG

3
Capitol Report: Theranos closes deal with Fortress to shut down embattled firm

2018-09-13 marketwatch
Fortress takes ownership of the company’s patents but leaves its remaining cash for distribution to unsecured creditors
FIG

3
The Theranos Saga Ends, Company Closes its Doors for Good

2018-09-06 biospace
Hours after it was reported that Elizabeth Holmes was shutting down Theranos for good, the company’s website has gone dark.
FIG JEF

3
PRESS DIGEST- British Business - Sept 6

2018-09-06 reuters
Sept 6 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
FIG MLSPY MRO MLSRF MLSPF

3
Theranos, scandal-plagued blood testing startup, to shut down

2018-09-05 sfgate
Theranos is going out with barely a whisper. Once heralded as a revolutionary new way to conduct a blood test to detect myriad diseases, all with a single finger prick, the company is making preparations to close its operations, according to a letter sent to shareholders.
FIG

3
Embattled blood-testing firm Theranos to dissolve: WSJ

2018-09-05 channelnewsasia
Theranos Inc, the once-celebrated Silicon Valley blood-testing firm, is about to dissolve itself months after top executives were indicted for defrauding investors, the Wall Street Journal reported on Wednesday.
FIG JEF

6
Embattled Blood-Testing Startup Theranos to Shut Down

2018-09-05 investorplace
Theranos is the blood-testing company that promised to provide customers with a revolutionary new way to test blood. However, the claims that it made were false and it was actually using normal blood-testing machines behind the scenes.
FIG WBA

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to FIG / Fortress Investment Group LLC on message board site Silicon Investor.

Point and Figure Charting Point and Figure Charting Point and Figure Charting Dorsey Wright u0026 Associates. Point and Figure Dorsey Wright u0026 Associates. Point and Figure Dorsey Wright u0026 Associates. Point and Figure
ILLEGAL IMMIGRATION THE FIGHT TO KEEP OUR DEMOCRACY ILLEGAL IMMIGRATION THE FIGHT TO KEEP OUR DEMOCRACY ILLEGAL IMMIGRATION THE FIGHT TO KEEP OUR DEMOCRACY GFI Group Inc. (GFIG) GFI Group Inc. (GFIG) GFI Group Inc. (GFIG)
New reconfigurable supercomputer that fits on your desktop New reconfigurable supercomputer that fits on your desktop New reconfigurable supercomputer that fits on your desktop Argue u0026 Fight about it here! Just step outside - to here! Argue u0026 Fight about it here! Just step outside - to here! Argue u0026 Fight about it here! Just step outside - to here!
do you wanna fight? do you wanna fight? do you wanna fight? Point and Figure Archive Thread Point and Figure Archive Thread Point and Figure Archive Thread
The Fight Thread! Come here to Pick a fight The Fight Thread! Come here to Pick a fight The Fight Thread! Come here to Pick a fight Trade/Invest with Options Jerry a Point u0026 Figure Chartist Trade/Invest with Options Jerry a Point u0026 Figure Chartist Trade/Invest with Options Jerry a Point u0026 Figure Chartist
CUSIP: 34958B106